In this edition:
GLP-1 RAs vs. insulin in early- vs. late-onset T2D
Self-reported physical activity & CV events/all-cause mortality in T2D
CATALYST: mifepristone in difficult-to-control T2D with hypercortisolism
REDEFINE 2: semaglutide-cagrilintide in T2D with overweight/obesity
TIRTLE1: tirzepatide in T1D with overweight/obesity
ATTAIN-1: orforglipron (oral, small-molecule GLP-1 RA) in obesity
STEP UP: semaglutide & eating control/behaviours
STEP UP: semaglutide & body composition
SURPASS-CVOT: CV outcomes with tirzepatide vs. dulaglutide
SURPASS-CVOT: kidney outcomes with tirzepatide vs. dulaglutide
Please login below to download this issue (PDF)